Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) is a synthetic, non-proteinogenic amino acid that acts as a potent and highly selective orthosteric agonist of the AMPA subtype of ionotropic glutamate receptors (AMPARs). AMPARs are ligand-gated cation channels composed of tetrameric assemblies of four subunits (GluA1–GluA4, encoded by GRIA1–GRIA4) that mediate the vast majority of fast excitatory synaptic transmission in the mammalian central nervous system. By binding to the orthosteric site of these receptors, AMPA induces a conformational change that opens the channel pore, allowing the influx of sodium (and in some cases calcium) ions, which depolarizes the postsynaptic membrane. AMPA is widely utilized as a standard pharmacological research tool and reference agonist in neurobiology to characterize non-NMDA receptor currents, study synaptic plasticity (such as long-term potentiation and long-term depression), and model excitotoxicity in vitro and in vivo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.